• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Thyroid Hormones and Thyromimetics: A New Approach to Nonalcoholic Steatohepatitis?

作者信息

Sinha Rohit A, Bruinstroop Eveline, Singh Brijesh K, Yen Paul M

机构信息

Departmet of Endocrinology, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, India.

Departmet of Endocrinology, Amsterdam UMC-Locatie VUMC, Amsterdam, the Netherlands.

出版信息

Hepatology. 2020 Aug;72(2):770-771. doi: 10.1002/hep.31204.

DOI:10.1002/hep.31204
PMID:32104916
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7496265/
Abstract
摘要

相似文献

1
Thyroid Hormones and Thyromimetics: A New Approach to Nonalcoholic Steatohepatitis?甲状腺激素与拟甲状腺素：非酒精性脂肪性肝炎的新疗法？
Hepatology. 2020 Aug;72(2):770-771. doi: 10.1002/hep.31204.
2
Thyromimetics as emerging therapeutic agents for nonalcoholic steatohepatitis: rationale for the development of resmetirom (MGL-3196).甲状腺模拟物作为非酒精性脂肪性肝炎的新型治疗药物：resmetirom（MGL-3196）的研发原理
Expert Opin Investig Drugs. 2020 Feb;29(2):99-101. doi: 10.1080/13543784.2020.1708899. Epub 2019 Dec 25.
3
Improving NASH with a little help from thyromimetics.在甲状腺激素类似物的些许帮助下改善非酒精性脂肪性肝炎。
Lancet. 2019 Nov 30;394(10213):1970-1972. doi: 10.1016/S0140-6736(19)32731-X. Epub 2019 Nov 15.
4
Intrahepatic hypothyroidism in MASLD: Role of liver-specific thyromimetics including resmetirom.非酒精性脂肪性肝病合并肝内甲状腺功能减退：包括瑞美替昂在内的肝脏特异性甲状腺激素模拟物的作用
Diabetes Metab Syndr. 2024 May;18(5):103034. doi: 10.1016/j.dsx.2024.103034. Epub 2024 May 4.
5
Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.Resmetirom（MGL-3196）治疗非酒精性脂肪性肝炎：一项多中心、随机、双盲、安慰剂对照的 2 期临床试验。
Lancet. 2019 Nov 30;394(10213):2012-2024. doi: 10.1016/S0140-6736(19)32517-6. Epub 2019 Nov 11.
6
Resmetirom, the first approved drug for the management of metabolic dysfunction-associated steatohepatitis: Trials, opportunities, and challenges.瑞美替隆，首个获批用于治疗代谢功能障碍相关脂肪性肝炎的药物：试验、机遇与挑战。
Metabolism. 2024 May;154:155835. doi: 10.1016/j.metabol.2024.155835. Epub 2024 Mar 19.
7
Development of Thyroid Hormones and Synthetic Thyromimetics in Non-Alcoholic Fatty Liver Disease.甲状腺激素与合成甲状腺刺激素在非酒精性脂肪性肝病中的作用。
Int J Mol Sci. 2022 Jan 20;23(3):1102. doi: 10.3390/ijms23031102.
8
Resmetirom: First Approval.雷美替胺：首次获批
Drugs. 2024 Jun;84(6):729-735. doi: 10.1007/s40265-024-02045-0. Epub 2024 May 21.
9
Thyroid hormone analogs for the treatment of dyslipidemia: past, present, and future.用于治疗血脂异常的甲状腺激素类似物：过去、现在与未来。
Curr Med Res Opin. 2017 Nov;33(11):1985-1993. doi: 10.1080/03007995.2017.1330259. Epub 2017 Jun 9.
10
Resmetirom (Rezdiffra) for metabolic dysfunction-associated steatohepatitis.用于治疗代谢功能障碍相关脂肪性肝炎的雷斯美洛（Rezdiffra）
Med Lett Drugs Ther. 2024 Apr 29;66(1701):65-66. doi: 10.58347/tml.2024.1701a.

引用本文的文献

1
Beneficial effects of MGL-3196 and BAM15 combination in a mouse model of fatty liver disease.MGL-3196 和 BAM15 联合治疗在脂肪肝疾病小鼠模型中的有益作用。
Acta Physiol (Oxf). 2024 Oct;240(10):e14217. doi: 10.1111/apha.14217. Epub 2024 Aug 16.
2
Systemic impacts of metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) on heart, muscle, and kidney related diseases.代谢功能障碍相关脂肪性肝病（MASLD）和代谢功能障碍相关脂肪性肝炎（MASH）对心脏、肌肉和肾脏相关疾病的全身影响。
Front Cell Dev Biol. 2024 Jul 16;12:1433857. doi: 10.3389/fcell.2024.1433857. eCollection 2024.
3
Molecular Aspects of MAFLD-New Insights on Pathogenesis and Treatment.MAFLD的分子层面——发病机制与治疗的新见解
Curr Issues Mol Biol. 2023 Nov 15;45(11):9132-9148. doi: 10.3390/cimb45110573.
4
Understanding the Relationship between Nonalcoholic Fatty Liver Disease and Thyroid Disease.了解非酒精性脂肪性肝病与甲状腺疾病的关系。
Int J Mol Sci. 2023 Sep 27;24(19):14605. doi: 10.3390/ijms241914605.
5
ULK1 Signaling in the Liver: Autophagy Dependent and Independent Actions.肝脏中的ULK1信号传导：自噬依赖性和非依赖性作用
Front Cell Dev Biol. 2022 Feb 18;10:836021. doi: 10.3389/fcell.2022.836021. eCollection 2022.
6
The New Therapeutic Approaches in the Treatment of Non-Alcoholic Fatty Liver Disease.新型治疗方法在非酒精性脂肪性肝病治疗中的应用。
Int J Mol Sci. 2021 Dec 8;22(24):13219. doi: 10.3390/ijms222413219.
7
Abnormal transaminase and lipid profiles in coexisting diseases in patients with fatty liver: a population study in Sichuan.四川地区共存疾病患者的肝功能酶和血脂谱异常：一项人群研究。
Biosci Rep. 2021 Dec 22;41(12). doi: 10.1042/BSR20211769.
8
Novel therapeutic targets for cholestatic and fatty liver disease.胆汁淤积性和脂肪性肝病的新型治疗靶点。
Gut. 2022 Jan;71(1):194-209. doi: 10.1136/gutjnl-2021-324305. Epub 2021 Oct 6.
9
Perspectives on Precision Medicine Approaches to NAFLD Diagnosis and Management.精准医学方法在非酒精性脂肪性肝病诊断和管理中的应用展望。
Adv Ther. 2021 May;38(5):2130-2158. doi: 10.1007/s12325-021-01690-1. Epub 2021 Apr 7.
10
Current treatment paradigms and emerging therapies for NAFLD/NASH.NAFLD/NASH 的现行治疗模式和新兴疗法。
Front Biosci (Landmark Ed). 2021 Jan 1;26(2):206-237. doi: 10.2741/4892.

本文引用的文献

1
Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.Resmetirom（MGL-3196）治疗非酒精性脂肪性肝炎：一项多中心、随机、双盲、安慰剂对照的 2 期临床试验。
Lancet. 2019 Nov 30;394(10213):2012-2024. doi: 10.1016/S0140-6736(19)32517-6. Epub 2019 Nov 11.
2
Nonalcoholic Fatty Liver Disease and Hypercholesterolemia: Roles of Thyroid Hormones, Metabolites, and Agonists.非酒精性脂肪性肝病与高胆固醇血症：甲状腺激素、代谢物和激动剂的作用。
Thyroid. 2019 Sep;29(9):1173-1191. doi: 10.1089/thy.2018.0664.
3
Association of non-alcoholic fatty liver disease with thyroid function: A systematic review and meta-analysis.非酒精性脂肪性肝病与甲状腺功能的关系：系统评价和荟萃分析。
Dig Liver Dis. 2018 Nov;50(11):1153-1162. doi: 10.1016/j.dld.2018.08.012. Epub 2018 Aug 23.
4
Low-Dose Levothyroxine Reduces Intrahepatic Lipid Content in Patients With Type 2 Diabetes Mellitus and NAFLD.低剂量左甲状腺素可降低 2 型糖尿病合并非酒精性脂肪性肝病患者的肝内脂质含量。
J Clin Endocrinol Metab. 2018 Jul 1;103(7):2698-2706. doi: 10.1210/jc.2018-00475.
5
Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention.非酒精性脂肪性肝病和非酒精性脂肪性肝炎的全球负担：趋势、预测、危险因素和预防。
Nat Rev Gastroenterol Hepatol. 2018 Jan;15(1):11-20. doi: 10.1038/nrgastro.2017.109. Epub 2017 Sep 20.
6
Association of noninvasive quantitative decline in liver fat content on MRI with histologic response in nonalcoholic steatohepatitis.非酒精性脂肪性肝炎中MRI上肝脏脂肪含量的无创定量下降与组织学反应的相关性
Therap Adv Gastroenterol. 2016 Sep;9(5):692-701. doi: 10.1177/1756283X16656735. Epub 2016 Jul 5.
7
Thyroid hormone stimulates hepatic lipid catabolism via activation of autophagy.甲状腺激素通过激活自噬作用刺激肝脏脂质分解代谢。
J Clin Invest. 2012 Jul;122(7):2428-38. doi: 10.1172/JCI60580. Epub 2012 Jun 11.
8
Thyroid hormone-related regulation of gene expression in human fatty liver.甲状腺激素对人类脂肪肝中基因表达的相关调节作用
J Clin Endocrinol Metab. 2009 Sep;94(9):3521-9. doi: 10.1210/jc.2009-0212. Epub 2009 Jun 23.